Presentation Information
[O-09-5]Impact of lecanemab on health outcomes in Alzheimer's disease from a Japanese societal perspective
Ataru Igarashi1, Mayaka Tani2, Mie Azuma2, Takuro Utsumi2, Carolyn Bodnar3, Se Ryeong Jang4, Hidetoshi Shibahara5, Sachie Inoue5, Oliver Burn6, Kate Molloy6, David Truman6, Gaku Kamanaka2, Yuta Kamada4, Yukinori Sakata2, Kiyoyuki Tomita2 (1.Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan, 2.Eisai Co.,Ltd., Japan, 3.Eisai Europe Ltd., UK, 4.Eisai Inc., USA, 5.Crecon Medical Assessment, Japan, 6.Source Health Economics, UK)